Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report
- Agnandji, Selidji T
- Csaki Huttner, Angela
- Zinser, Madeleine E
- Njuguna, Patricia
- Dahlke, Christine
- Fernandes, José F
- Yerly, Sabine
- Dayer, Julie-Anne
- Kraehling, Verena
- Kasonta, Rahel
- Adegnika, Akim A
- Altfeld, Marcus
- Auderset, Floriane
- Bache, Emmanuel B
- Biedenkopf, Nadine
- Borregaard, Saskia
- Brosnahan, Jessica S
- Burrow, Rebekah
- Combescure, Christophe
- Desmeules, Jules Alexandre
- Eickmann, Markus
- Fehling, Sarah K
- Finckh, Axel
- Goncalves Cabecinhas, Ana Rita
- Grobusch, Martin P
- Hooper, Jay
- Jambrecina, Alen
- Kabwende, Anita L
- Kaya, Gurkan
- Kimani, Domtila
- Lell, Bertrand
- Lemaître, Barbara
- Lohse, Ansgar W
- Massinga-Loembe, Marguerite
- Matthey, Alain
- Mordmüller, Benjamin
- Nolting, Anne
- Ogwang, Caroline
- Ramharter, Michael
- Schmidt-Chanasit, Jonas
- Schmiedel, Stefan
- Silvera, Peter
- Stahl, Felix R
- Staines, Henry M
- Strecker, Thomas
- Stubbe, Hans C
- Tsofa, Benjamin
- Zaki, Sherif
- Fast, Patricia
- Moorthy, Vasee
- Kaiser, Laurent
- Krishna, Sanjeev
- Becker, Stephan
- Kieny, Marie-Paule
- Bejon, Philip
- Kremsner, Peter G
- Addo, Marylyn M
- Siegrist, Claire-Anne
- VSV Ebola Consortium (VEBCON)
DOIAbstract
The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa
Add to ORKG